X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs DR. REDDYS LAB - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. DR. REDDYS LAB WOCKHARDT LTD./
DR. REDDYS LAB
 
P/E (TTM) x -15.8 29.9 - View Chart
P/BV x 2.6 2.9 88.3% View Chart
Dividend Yield % 1.3 0.9 138.2%  

Financials

 WOCKHARDT LTD.   DR. REDDYS LAB
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
DR. REDDYS LAB
Mar-17
WOCKHARDT LTD./
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1293,397 33.2%   
Low Rs6272,560 24.5%   
Sales per share (Unadj.) Rs363.1856.5 42.4%  
Earnings per share (Unadj.) Rs-20.478.0 -26.2%  
Cash flow per share (Unadj.) Rs-7.0139.9 -5.0%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.10.7 169.6%  
Book value per share (Unadj.) Rs301.8739.8 40.8%  
Shares outstanding (eoy) m110.55165.74 66.7%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x2.43.5 69.5%   
Avg P/E ratio x-42.938.2 -112.4%  
P/CF ratio (eoy) x-125.921.3 -591.3%  
Price / Book Value ratio x2.94.0 72.3%  
Dividend payout %-48.925.7 -190.6%   
Avg Mkt Cap Rs m97,063493,632 19.7%   
No. of employees `0006.822.7 29.8%   
Total wages/salary Rs m9,66531,068 31.1%   
Avg. sales/employee Rs Th5,931.86,259.0 94.8%   
Avg. wages/employee Rs Th1,428.11,369.8 104.3%   
Avg. net profit/employee Rs Th-334.0569.7 -58.6%   
INCOME DATA
Net Sales Rs m40,146141,961 28.3%  
Other income Rs m1,1431,715 66.6%   
Total revenues Rs m41,289143,676 28.7%   
Gross profit Rs m12824,722 0.5%  
Depreciation Rs m1,48910,266 14.5%   
Interest Rs m2,253634 355.3%   
Profit before tax Rs m-2,47215,537 -15.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2112,965 -7.1%   
Profit after tax Rs m-2,26012,921 -17.5%  
Gross profit margin %0.317.4 1.8%  
Effective tax rate %8.519.1 44.8%   
Net profit margin %-5.69.1 -61.9%  
BALANCE SHEET DATA
Current assets Rs m46,16096,837 47.7%   
Current liabilities Rs m19,25884,199 22.9%   
Net working cap to sales %67.08.9 752.7%  
Current ratio x2.41.2 208.4%  
Inventory Days Days10173 137.3%  
Debtors Days Days9498 96.3%  
Net fixed assets Rs m40,165102,552 39.2%   
Share capital Rs m553829 66.7%   
"Free" reserves Rs m32,814121,792 26.9%   
Net worth Rs m33,367122,621 27.2%   
Long term debt Rs m31,9035,449 585.5%   
Total assets Rs m89,687218,165 41.1%  
Interest coverage x-0.125.5 -0.4%   
Debt to equity ratio x1.00 2,151.6%  
Sales to assets ratio x0.40.7 68.8%   
Return on assets %06.2 -0.1%  
Return on equity %-6.810.5 -64.3%  
Return on capital %-0.312.9 -2.6%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m9,12181,670 11.2%   
Fx outflow Rs m2,13326,355 8.1%   
Net fx Rs m6,98855,315 12.6%   
CASH FLOW
From Operations Rs m-2,69521,444 -12.6%  
From Investments Rs m-6,863-18,404 37.3%  
From Financial Activity Rs m12,545-3,692 -339.8%  
Net Cashflow Rs m3,010-1,144 -263.1%  

Share Holding

Indian Promoters % 74.5 25.5 292.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.4 42.6%  
FIIs % 7.7 35.3 21.8%  
ADR/GDR % 0.1 18.5 0.5%  
Free float % 15.4 15.3 100.7%  
Shareholders   67,757 75,885 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS